Pharma DECODED
Latest edition: 17 May 2024
Share newsletter
Get the full version straight to your inbox.
Exclusive access to our best-in-class data & intelligence
Subscribe now
Spotlight
Patient access to medicines must be the focus of US drug pricing policy
Amidst congressional action and changes in payer pricing models, experts discuss what must be done for patients to reap benefits.
Latest news
FDA grants breakthrough therapy status for Nuvalent's NVL-655
The FDA granted BTD based on the initial data from the Phase I segment of the Phase I/II ALKOVE-1 trial in NSCLC patients.
Ionis and Biogen discontinue experimental ALS drug after Phase I/II flop
The ALS space took another hit after experimental drug BIIB105 failed to show evidence of benefit in patients in the Phase I/II ALSpire trial.
Food Allergy Awareness Week 2024: How can new treatments target an unmet need?
IgGenix is planning to initiate a clinical trial later this year investigating its peanut allergy monoclonal antibody IGXN001.
Roche targets obesity market with early positive trial data
Roche’s GLP-1/GIP receptor agonist, which was gained in the Carmot acquisition, showed an 18.8% weight loss in a Phase Ib trial.
Bayer's non-hormonal therapy reduces hot flashes in Phase III trials
Bayer’s non-hormonal therapy, elinzanetant, reduced the frequency and severity of hot flashes associated with menopause in two Phase III trials.
Parallel Bio launches Clinical Trial in a Dish to predict drug efficacy
The Clinical Trial in a Dish approach mirrors the human immune response and patient diversity.
Eli Lilly's efsitora alfa shows promise in Phase III T2D trials
Once-weekly insulin efsitora alfa offered non-inferior A1C reduction in the QWINT-2 and QWINT-4 trials.
In our previous edition
Pharma Decoded
KRAS inhibitors: The next frontier beckons
16 May 2024
Pharma Decoded
Circular RNA: Vaccines, therapeutics and biomarkers could be revolutionised
15 May 2024
Pharma Decoded
Sanofi to make €1bn biomanufacturing investment in France
14 May 2024
Still looking?
Search companies, themes, reports, as well as actionable data & insights spanning 22 global industries
Explorer
Access more premium companies when you subscribe to Explorer